HOME >> MEDICINE >> NEWS
Trial shows malaria vaccine could protect young children from disease for 18 months

The RTS, S/AS02A vaccine could protect young African children against a range of clinical disease caused by the malaria parasite for at least 18 months, concludes a randomised trial published online today (Tuesday November 15, 2005) by The Lancet.

Early trials of the RTS, S/AS02A vaccine have shown that the vaccine is safe, well tolerated, and can trigger an immune response. In one of the trials, involving over 2000 Mozambican children aged 1-4 years, Pedro Alonso (University of Barcelona, Spain) and colleagues found that after 6 months' follow-up the vaccine reduced the risk of clinical malaria by 30%, delayed time to first infection by 45%, and reduced the risk of severe malaria by 58%. In the latest study the investigators followed-up the children for a further 12 months. They found that the efficacy of the drug did not wane and that protection against clinical malaria lasted for at least 18 months after vaccination. The study shows that the vaccine reduces the risk of clinical malaria by 35% and nearly halves the risk of severe malaria over a period of 18 months.

Professor Alonso states: "Our results show that the RTS,S/AS02A candidate malaria vaccine confers partial protection for at least 18 months against a range of clinical diseases caused by P falciparum in children living in a rural malaria endemic area of African The combination of sustained protection together with substantial prevention of the severe forms of malaria marks RTS, S/AS02A as a promising vaccine candidate and strongly suggests that malaria vaccines have an important role as future public-health instruments."

The publication coincides with a presentation at the Fourth Multilateral Initiative on Malaria Pan-African Malaria Conference 2005 in Yaounde, Cameroon.


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
15-Nov-2005


Page: 1

Related medicine news :

1. Trial stops after stroke and mortality significantly reduced by blood
2. Trials underway for essential new TB vaccine
3. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
4. ENDEAVOR III Trial reports key findings on new-generation stent
5. NIH names Clinical Trial Units for the Microbicide Trials Network
6. Clinical Trials Units selected for newly restructured HIV/AIDS research networks
7. The Public Library of Science launches the new open access journal PLoS Clinical Trials
8. Trial shows vaccine against cervical cancer provides long-term protection
9. Trial demonstrates new drugs effectiveness against psoriasis
10. Trial at Jefferson shows new drug may help cancer patients who need stem cell transplants
11. Second implant of US Pilot Trial achieved

Post Your Comments:
(Date:8/29/2015)... ... August 29, 2015 , ... ... freely market and sell Arterosil and Arterosil HP, and that all claims and ... sued Vascular Health Sciences, LLC (VHS) in the United States District Court for ...
(Date:8/28/2015)... ... August 28, 2015 , ... Joining a ... Memorial Hospital recently transitioned management companies to partner with Wound Care Advantage (WCA) ... outpatient wound center. , Transitioning wound care management providers can be a ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately ... the Zoo to celebrate children helping children, a thank you to the many ... Ohio have contributed to the United Methodist initiative to end malaria deaths. , ...
(Date:8/28/2015)... CA (PRWEB) , ... August 28, 2015 , ... An ... journey that local pizza maker Paul LaRocco has gone through to open a pizzeria ... approval and permitting process tends to take several months, but the current process, having ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing for ... subsidiary USPI Tenet Health. , The American Heart Association hosts their well-known Heart Walk ... believe that together, a difference can be made. Walkers can participate in the cause ...
Breaking Medicine News(10 mins):Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2
(Date:8/28/2015)... N.C. , Aug. 28, 2015  Delays ... research projects can slow down the decision-making process, ... is, therefore, absolutely critical for biopharmaceutical companies to ... research approval process for quicker and more meaningful ... by Best Practices, LLC, nearly three-quarters of benchmarked ...
(Date:8/28/2015)... Research and Markets ... the "12th Annual Report and Survey of ... their offering. The 2015 12th Annual ... Production is the most recent study of biotherapeutic ... future capacity and production. The report contains the ...
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rktnl9/investigation ... "Investigation Report on China,s Insulin Aspart Market, 2010-2019" ... by Novo Nordisk, insulin aspart (under the trade ... the treatment of diabetes. Compared with human insulin, ... starts working fast and reports higher peak of ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
Cached News: